A prospective cohort study of patients with peripheral T-cell lymphoma in the United States

Kenneth R. Carson, Steven M. Horwitz, Lauren C. Pinter-Brown, Steven T. Rosen, Barbara Pro, Eric D. Hsi, Massimo Federico, Christian Gisselbrecht, Marc Schwartz, Lisa A. Bellm, Mark A. Acosta, Andrei R. Shustov, Ranjana H. Advani, Tatyana A. Feldman, Mary Jo Lechowicz, Sonali M. Smith, Frederick Lansigan, Anil Tulpule, Michael D. Craig, John P. Greer & 6 others Brad S. Kahl, Joseph W. Leach, Neil Morganstein, Carla Casulo, Steven I. Park, Francine M. Foss

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

BACKGROUND: Long-term survival in patients with aggressive peripheral T-cell lymphoma (PTCL) is generally poor, and there currently is no clear consensus regarding the initial therapy used for these diseases. Herein, the authors analyzed treatment patterns and outcomes in a prospectively collected cohort of patients with a new diagnosis of nodal PTCL in the United States. METHODS: Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment (COMPLETE) is a prospective multicenter cohort study designed to identify the most common prevailing treatment patterns used for patients newly diagnosed with PTCL in the United States. Patients with nodal PTCL and completed records regarding baseline characteristics and initial therapy were included in this analysis. All statistical tests were 2-sided. RESULTS: Of a total of 499 patients enrolled, 256 (51.3%) had nodal PTCL and completed treatment records. As initial therapy, patients received doxorubicin-containing regimens (41.8%), regimens containing doxorubicin plus etoposide (20.9%), other etoposide regimens (15.8%), other single-agent or combination regimens (19.2%), and gemcitabine-containing regimens (2.1%). Survival was found to be statistically significantly longer for patients who received doxorubicin (log-rank P =.03). After controlling for disease histology and International Prognostic Index, results demonstrated a trend toward significance in mortality reduction in patients who received doxorubicin compared with those who did not (hazard ratio, 0.71; 95% confidence interval, 0.48-1.05 [P =.09]). CONCLUSIONS: To the authors' knowledge, there is no clear standard of care in the treatment of patients with PTCL in the United States. Although efforts to improve frontline treatments are necessary, anthracyclines remain an important component of initial therapy for curative intent. Cancer 2017;123:1174–1183.

Original languageEnglish (US)
Pages (from-to)1174-1183
Number of pages10
JournalCancer
Volume123
Issue number7
DOIs
StatePublished - Apr 1 2017

Fingerprint

Peripheral T-Cell Lymphoma
Cohort Studies
Prospective Studies
Doxorubicin
Therapeutics
Etoposide
gemcitabine
Survival
Anthracyclines
Standard of Care
Multicenter Studies
Histology
Confidence Intervals

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Carson, K. R., Horwitz, S. M., Pinter-Brown, L. C., Rosen, S. T., Pro, B., Hsi, E. D., ... Foss, F. M. (2017). A prospective cohort study of patients with peripheral T-cell lymphoma in the United States. Cancer, 123(7), 1174-1183. https://doi.org/10.1002/cncr.30416
Carson, Kenneth R. ; Horwitz, Steven M. ; Pinter-Brown, Lauren C. ; Rosen, Steven T. ; Pro, Barbara ; Hsi, Eric D. ; Federico, Massimo ; Gisselbrecht, Christian ; Schwartz, Marc ; Bellm, Lisa A. ; Acosta, Mark A. ; Shustov, Andrei R. ; Advani, Ranjana H. ; Feldman, Tatyana A. ; Lechowicz, Mary Jo ; Smith, Sonali M. ; Lansigan, Frederick ; Tulpule, Anil ; Craig, Michael D. ; Greer, John P. ; Kahl, Brad S. ; Leach, Joseph W. ; Morganstein, Neil ; Casulo, Carla ; Park, Steven I. ; Foss, Francine M. / A prospective cohort study of patients with peripheral T-cell lymphoma in the United States. In: Cancer. 2017 ; Vol. 123, No. 7. pp. 1174-1183.
@article{0fb50d12d830494788890d1aed6b8c5d,
title = "A prospective cohort study of patients with peripheral T-cell lymphoma in the United States",
abstract = "BACKGROUND: Long-term survival in patients with aggressive peripheral T-cell lymphoma (PTCL) is generally poor, and there currently is no clear consensus regarding the initial therapy used for these diseases. Herein, the authors analyzed treatment patterns and outcomes in a prospectively collected cohort of patients with a new diagnosis of nodal PTCL in the United States. METHODS: Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment (COMPLETE) is a prospective multicenter cohort study designed to identify the most common prevailing treatment patterns used for patients newly diagnosed with PTCL in the United States. Patients with nodal PTCL and completed records regarding baseline characteristics and initial therapy were included in this analysis. All statistical tests were 2-sided. RESULTS: Of a total of 499 patients enrolled, 256 (51.3{\%}) had nodal PTCL and completed treatment records. As initial therapy, patients received doxorubicin-containing regimens (41.8{\%}), regimens containing doxorubicin plus etoposide (20.9{\%}), other etoposide regimens (15.8{\%}), other single-agent or combination regimens (19.2{\%}), and gemcitabine-containing regimens (2.1{\%}). Survival was found to be statistically significantly longer for patients who received doxorubicin (log-rank P =.03). After controlling for disease histology and International Prognostic Index, results demonstrated a trend toward significance in mortality reduction in patients who received doxorubicin compared with those who did not (hazard ratio, 0.71; 95{\%} confidence interval, 0.48-1.05 [P =.09]). CONCLUSIONS: To the authors' knowledge, there is no clear standard of care in the treatment of patients with PTCL in the United States. Although efforts to improve frontline treatments are necessary, anthracyclines remain an important component of initial therapy for curative intent. Cancer 2017;123:1174–1183.",
author = "Carson, {Kenneth R.} and Horwitz, {Steven M.} and Pinter-Brown, {Lauren C.} and Rosen, {Steven T.} and Barbara Pro and Hsi, {Eric D.} and Massimo Federico and Christian Gisselbrecht and Marc Schwartz and Bellm, {Lisa A.} and Acosta, {Mark A.} and Shustov, {Andrei R.} and Advani, {Ranjana H.} and Feldman, {Tatyana A.} and Lechowicz, {Mary Jo} and Smith, {Sonali M.} and Frederick Lansigan and Anil Tulpule and Craig, {Michael D.} and Greer, {John P.} and Kahl, {Brad S.} and Leach, {Joseph W.} and Neil Morganstein and Carla Casulo and Park, {Steven I.} and Foss, {Francine M.}",
year = "2017",
month = "4",
day = "1",
doi = "10.1002/cncr.30416",
language = "English (US)",
volume = "123",
pages = "1174--1183",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

Carson, KR, Horwitz, SM, Pinter-Brown, LC, Rosen, ST, Pro, B, Hsi, ED, Federico, M, Gisselbrecht, C, Schwartz, M, Bellm, LA, Acosta, MA, Shustov, AR, Advani, RH, Feldman, TA, Lechowicz, MJ, Smith, SM, Lansigan, F, Tulpule, A, Craig, MD, Greer, JP, Kahl, BS, Leach, JW, Morganstein, N, Casulo, C, Park, SI & Foss, FM 2017, 'A prospective cohort study of patients with peripheral T-cell lymphoma in the United States', Cancer, vol. 123, no. 7, pp. 1174-1183. https://doi.org/10.1002/cncr.30416

A prospective cohort study of patients with peripheral T-cell lymphoma in the United States. / Carson, Kenneth R.; Horwitz, Steven M.; Pinter-Brown, Lauren C.; Rosen, Steven T.; Pro, Barbara; Hsi, Eric D.; Federico, Massimo; Gisselbrecht, Christian; Schwartz, Marc; Bellm, Lisa A.; Acosta, Mark A.; Shustov, Andrei R.; Advani, Ranjana H.; Feldman, Tatyana A.; Lechowicz, Mary Jo; Smith, Sonali M.; Lansigan, Frederick; Tulpule, Anil; Craig, Michael D.; Greer, John P.; Kahl, Brad S.; Leach, Joseph W.; Morganstein, Neil; Casulo, Carla; Park, Steven I.; Foss, Francine M.

In: Cancer, Vol. 123, No. 7, 01.04.2017, p. 1174-1183.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A prospective cohort study of patients with peripheral T-cell lymphoma in the United States

AU - Carson, Kenneth R.

AU - Horwitz, Steven M.

AU - Pinter-Brown, Lauren C.

AU - Rosen, Steven T.

AU - Pro, Barbara

AU - Hsi, Eric D.

AU - Federico, Massimo

AU - Gisselbrecht, Christian

AU - Schwartz, Marc

AU - Bellm, Lisa A.

AU - Acosta, Mark A.

AU - Shustov, Andrei R.

AU - Advani, Ranjana H.

AU - Feldman, Tatyana A.

AU - Lechowicz, Mary Jo

AU - Smith, Sonali M.

AU - Lansigan, Frederick

AU - Tulpule, Anil

AU - Craig, Michael D.

AU - Greer, John P.

AU - Kahl, Brad S.

AU - Leach, Joseph W.

AU - Morganstein, Neil

AU - Casulo, Carla

AU - Park, Steven I.

AU - Foss, Francine M.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - BACKGROUND: Long-term survival in patients with aggressive peripheral T-cell lymphoma (PTCL) is generally poor, and there currently is no clear consensus regarding the initial therapy used for these diseases. Herein, the authors analyzed treatment patterns and outcomes in a prospectively collected cohort of patients with a new diagnosis of nodal PTCL in the United States. METHODS: Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment (COMPLETE) is a prospective multicenter cohort study designed to identify the most common prevailing treatment patterns used for patients newly diagnosed with PTCL in the United States. Patients with nodal PTCL and completed records regarding baseline characteristics and initial therapy were included in this analysis. All statistical tests were 2-sided. RESULTS: Of a total of 499 patients enrolled, 256 (51.3%) had nodal PTCL and completed treatment records. As initial therapy, patients received doxorubicin-containing regimens (41.8%), regimens containing doxorubicin plus etoposide (20.9%), other etoposide regimens (15.8%), other single-agent or combination regimens (19.2%), and gemcitabine-containing regimens (2.1%). Survival was found to be statistically significantly longer for patients who received doxorubicin (log-rank P =.03). After controlling for disease histology and International Prognostic Index, results demonstrated a trend toward significance in mortality reduction in patients who received doxorubicin compared with those who did not (hazard ratio, 0.71; 95% confidence interval, 0.48-1.05 [P =.09]). CONCLUSIONS: To the authors' knowledge, there is no clear standard of care in the treatment of patients with PTCL in the United States. Although efforts to improve frontline treatments are necessary, anthracyclines remain an important component of initial therapy for curative intent. Cancer 2017;123:1174–1183.

AB - BACKGROUND: Long-term survival in patients with aggressive peripheral T-cell lymphoma (PTCL) is generally poor, and there currently is no clear consensus regarding the initial therapy used for these diseases. Herein, the authors analyzed treatment patterns and outcomes in a prospectively collected cohort of patients with a new diagnosis of nodal PTCL in the United States. METHODS: Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment (COMPLETE) is a prospective multicenter cohort study designed to identify the most common prevailing treatment patterns used for patients newly diagnosed with PTCL in the United States. Patients with nodal PTCL and completed records regarding baseline characteristics and initial therapy were included in this analysis. All statistical tests were 2-sided. RESULTS: Of a total of 499 patients enrolled, 256 (51.3%) had nodal PTCL and completed treatment records. As initial therapy, patients received doxorubicin-containing regimens (41.8%), regimens containing doxorubicin plus etoposide (20.9%), other etoposide regimens (15.8%), other single-agent or combination regimens (19.2%), and gemcitabine-containing regimens (2.1%). Survival was found to be statistically significantly longer for patients who received doxorubicin (log-rank P =.03). After controlling for disease histology and International Prognostic Index, results demonstrated a trend toward significance in mortality reduction in patients who received doxorubicin compared with those who did not (hazard ratio, 0.71; 95% confidence interval, 0.48-1.05 [P =.09]). CONCLUSIONS: To the authors' knowledge, there is no clear standard of care in the treatment of patients with PTCL in the United States. Although efforts to improve frontline treatments are necessary, anthracyclines remain an important component of initial therapy for curative intent. Cancer 2017;123:1174–1183.

UR - http://www.scopus.com/inward/record.url?scp=85006168553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006168553&partnerID=8YFLogxK

U2 - 10.1002/cncr.30416

DO - 10.1002/cncr.30416

M3 - Article

VL - 123

SP - 1174

EP - 1183

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 7

ER -

Carson KR, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED et al. A prospective cohort study of patients with peripheral T-cell lymphoma in the United States. Cancer. 2017 Apr 1;123(7):1174-1183. https://doi.org/10.1002/cncr.30416